The predictive role of p16 deletion, p53 deletion, and polysomy 9 and 17 in pancreatic ductal adenocarcinoma.
In this study, we investigated p53 and p16 deletions, and chromosome 9 and 17 amplifications in pancreatic ductal adenocarcinoma (PDAC), and further analyzed their associations with clinical characteristics and prognosis of PDAC. A total of 32 PDAC and 23 peritumoral tissues were collected. Molecular abnormalities of CEP9/p16 and CEP17/p53 were detected using Fluorescence in situ hybridization (FISH). Deletions of p16 and p53 were detected in 50 % and 65.7 % of PDAC, respectively. Polysomy 9 and 17 were identified in 75 % and 71.8 % of PDAC, respectively. No p16 and p53 deletion, polysomy 9 and 17 were identified in peritumoral tissues. We also observed significant correlations of p16 deletion, polysomy 9 and 17 with shorter survival of PDAC. P16 deletion, polysomy 9 and 17 are predictive markers for poor prognosis of PDAC patients, but p53 deletion is not associated with the clinical characteristics and prognosis of PDAC.
Experimental Research Center, First People's Hospital, Shanghai Jiaotong University, 85 Wujin Road, Shanghai 200080, China.
Yanli
Y
Luo
Ling
L
Tian
Ye
Y
Feng
Miaoying
M
Yi
Xiafang
X
Chen
Qian
Q
Huang
D000782:Aneuploidy; D021441:Carcinoma, Pancreatic Ductal / Q000737:chemistry / Q000175:diagnosis / Q000235:genetics*; D016009:Chi-Square Distribution; D002886:Chromosomes, Human, Pair 17; D002899:Chromosomes, Human, Pair 9; D005260:Female; D017353:Gene Deletion; D019942:Genes, p16; D016158:Genes, p53; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000737:chemistry / Q000175:diagnosis / Q000235:genetics*; D011379:Prognosis